BioFuture 2026 Conference Announces Agenda
News related to:Demy-Colton · 3 min read
NEW YORK, Sept. 29, 2026 /CourierPR/ -- BioFuture 2026, a two-day program featuring 100+ speakers and 50+ presenting companies, is set to explore the future of biopharma and healthcare. Taking place October 27-28 at Cure, 345 Park Avenue South in New York City, the conference will convene industry leaders from across biopharma, healthcare, investment, technology, and policy. The agenda for BioFuture™ 2026, which will run from October 27-28, will feature a diverse lineup of speakers and presenters.
The conference will feature discussions, company presentations, networking, and one-to-one partnering sessions. These will be followed by virtual partnering sessions from November 3-5. BioFuture allows innovators, investors, and industry decision-makers to examine the scientific, technological, financial, and policy developments shaping the future of biopharma. This year's program will span AI, oncology, neuroscience, MedTech, emerging therapeutics, biotech financing, regulatory, and policy issues, and global drug development.
Key speakers include Paul Hastings from Nkarta, Nouhad Husseini from Regeneron Pharmaceuticals, Alanna Temme from the Midsized Biotech Alliance of America, Priscilla VanderVeer from No Patient Left Behind, and Scott Barry from EW Healthcare Partners. The program will also include presentations from companies such as Piper Sandler, Mizuho Securities, Johnson & Johnson, Regeneron Pharmaceuticals, Schrödinger, Russo Partners, WuXi AppTec, Blue Matter, Cure, Evotec, Ipsen, Thermo Fisher Scientific, Big4Bio, HMA Consulting, Withum, and Hogan Lovells Cadwalader.
BioFuture will also feature one-hour, industry analyst-led Spotlight Panels that will highlight companies across biopharma, digital medicine, AI, TechBio, and other emerging areas. The Seed Showcase will allow early-stage companies to present their technologies and business models and receive real-time feedback from investors and industry leaders. Networking receptions and one-to-one partnering will create additional opportunities for attendees to connect with investors, potential partners, and other leaders across the life sciences ecosystem.
Some of the most important questions facing biopharma today can't be answered by science alone. Breakthrough innovation also depends on capital, policy, regulation, partnerships, and the ability to translate new technologies into medicines that reach patients. BioFuture brings those worlds together so leaders can challenge assumptions, exchange perspectives, and build relationships that can help move innovation forward.
The conference will include a wide range of topics, including Health as a Right vs. Health as a Business, where Paul Hastings, Nkarta; Nouhad Husseini, Regeneron Pharmaceuticals; Alanna Temme, Midsized Biotech Alliance of America; and Priscilla VanderVeer, No Patient Left Behind, will discuss. Another session will feature Scott Barry from EW Healthcare Partners, Kevin Eisele from William Blair, Dennis Purcell from Aisling Capital, and Robert Masella from Goodwin, who will discuss Funding Has Come Back: But Has It?.
Next Wave of Innovation: Navigating Policy and Regulatory Headwinds will be moderated by Lori Ellis from Open Door Salon, featuring Cartier Esham from Esham Strategies, Jennifer Hawks Bland from NewYorkBIO, William Soliman from ACMA, Blake Wilson from Hogan Lovells Cadwalader, and Susan Winckel from the Reagan-Udall Foundation. Leading the AI-First Biopharma Revolution: Faster Decisions. Faster Medicines. Better Outcomes will be moderated by MaryAnne Rizk from Rizk Management Advisors, featuring Maneesh Goyal from Mayo Clinic Platform, William Soliman from ACMA, and Fabio Thiers from ConverGen AI.
AI & Deep Tech: Refining Health Innovation, Drug Discovery, Diagnostics and Delivery will be moderated by Beth Rogozinski from Oncoustics, featuring Tara Austraat-Churik from Blue Matter, Karen Akinsanya from Schrödinger, Ingrid Müller from Evotec, and Rachel Ravens from 46Health. China: A Global Biotech Player will be moderated by Ignacio Guerrero-Ros from Russo Partners, featuring Zairan Liu from PharmCube, Josie Zhou from McKinsey & Company, and Maria Luisa Pineda from Envisagenics. Leveraging Deep Disease Area Expertise to Bring Transformational Medicines to Patients will be moderated by Jeremy Abbate from Scientific American, featuring John Reed from Johnson & Johnson.
BioFuture 2026 will be attended by leaders from biotechnology, pharmaceuticals, healthcare, technology, investment, and policy. The full agenda is available here. Registration for BioFuture 2026 is still open. Qualified investors and media may apply for complimentary registration.
BioFuture, produced by Demy-Colton, brings together leaders from biotechnology, pharmaceuticals, healthcare, technology, investment, and policy to explore the scientific, business, and societal forces shaping the future of biopharma. Through discussions, company presentations, partnering, and networking, BioFuture connects innovators with investors, strategic partners, and industry leaders across the healthcare ecosystem.